Good Sold more than 100,000 units of antigen tests in Q1 compared to 5k units last FY Sold less than supposed to due to limited stock, meaning more sales to come in Secured 20m tests Demand in Australia is rising More demand for HIV test
Bad Negative QoQ growth, which was expected after the Access Bio deal broke Only got a 2.4m one-off payment when the contract was more than 7m...(take or pay) HIV side of the business is taking up very slowly which supposed to be the main business No new market entry yet
